15 Filthy Spots That Survived Your Spring Cleaning Rampage, According to an Expert

CNET
Look outside and you'll see that flowers are blooming and pollen is flying. That means it's time to start spring cleaning -- or finish, according to a professional we spoke with.
The professional in question is Angie Olive, owner of Alliance Building Services in St. Louis and she just happens to be my mom. She's been in the cleaning business for 25 years and says there are more than a dozen spots in the home that almost everyone misses.
"Most things are out of sight and out of mind," said Olive, owner of . "If your outside surfaces are clean, you think everything is clean. It's no fault of your own that the stuff that slides down the side of your stove goes unnoticed until you move out."
"If you maintain cleaning your house throughout the year, you should still consider hiring a professional cleaning company to come in at least twice a year for a deep clean," she added.
So, if deep cleaning your home is part of your spring routine, here are 15 places in your home that you shouldn't forget.
1. Shutters
Built-in shutters can accumulate a lot of dust over the years. Although it seems the only solution is regular dusting, I have found a tool that makes it slightly easier: a blind cleaner duster brush.
Built-in shutters can often hide dust.
Corin Cesaric/CNET
(Tip: I also use this tool to clean my window AC unit, and you can also use it on blinds, too.)
2. Door frames
The top of door frames is another area known for almost always being dusty. You can use a duster, microfiber cloth or vacuum to clean that area, then with warm, soapy water for the rest of the frame.
3. Baseboards
Cleaning baseboards is typically on the list of least desirable chores. On Reddit, many users ask for tips on how to make this one easier on themselves -- and their backs and knees. One user suggested knee pads, while another advocates for using a vacuum with a brush attachment.
If you have pets or there's a lot of foot traffic in your home, you'll want to clean your baseboards at least twice a month.
FotoDuets/Getty Images
Olive suggests that after deep cleaning your baseboards once, you can maintain them by using a damp mop on them when cleaning your floors. "As long as you're not using harsh chemicals, it won't damage your paint," she said.
4. Under the couch and bed
For this chore, a robot vacuum may be the best -- and easiest -- option for regular upkeep. (CNET chose the Ecovacs Deebot T30S Combo and the iRobot Combo J7 Plus as the best robot vacuums for 2025.)
5. Ceiling fans
It's good to occasionally clean the entire ceiling fan, including the bulbs, but the blades typically need the most attention. If your blades are heavily covered in dust, use a vacuum cleaner with the wand attachment on them first to minimize the amount that falls onto the ground -- or worse, in your face -- before dusting them clean with a duster or microfiber cloth.
You can also clean the pull strings and bulbs with a microfiber cloth, but make sure the light switch is turned off and the bulbs have completely cooled before touching them.
If you're deep cleaning your home, don't forget to look up to find the areas you may have missed.
BackyardProduction/Getty Images
6. Grout
When I moved into my apartment a few years ago, I could never get the tiny bathroom to feel clean — until I scrubbed the grout and unveiled its true color. I used Zep Grout Cleaner and a grout brush and was amazed at the difference, as were many on TikTok who used the same product.
When I was halfway done with cleaning the grout, I was already extremely satisfied with the results.
Corin Cesaric/CNET
I poured the solution on the grout and let it sit for two to three minutes before using the brush to scrub the grout, then wiped the area clean. I now deep clean the grout about every six months and regularly mop.
7. Remote controls
Although most people touch their TV remotes every day, it's often forgotten that we need to clean them, too. "They might not look dirty, but they're usually full of germs," Olive said.
You should aim to clean and disinfect the remotes in your home about once a month.A quick way to clean your remote is to use a disinfectant wipe and then let it air dry.
8. Tops of cabinets
When you cook on your stovetop, the smoke, steam and food particles travel up and often settle on top of your cabinets. This leaves a thick, sticky residue if you forget to clean the area.
"Regularly clean with a degreaser on top of the cabinets," Olive said. "Once you get the build-up gone, you can maintain it."
Another way to protect the top of your cabinets from the buildup is to line them with parchment or wax paper.
9. Doorknobs
Doorknobs may not look dirty but most are teeming with germs.
Fotosearch/Getty Images
Doorknobs are another high-touch area that can be forgotten about. Use a disinfectant wipe or Lysol to clean them, especially during cold and flu season.
(Tip: Clean your light switches at the same time you clean your door knobs since they're typically near each other.)
10. Stove knobs
Stove knobs can get the same greasy residue buildup so it's important to deep clean them as well. Take the knobs off and soak them in warm, soapy water and scrub them if needed, then rinse, dry and replace.
11. Side of the stove
As your stove knobs are soaking, you can deep clean the side of your stove, too. Pull out the appliance and use a cleaner of your choice to get rid of any food buildup that may have accumulated.
"As you're cooking, you don't realize what you're spilling between the appliance and the countertop," Olive said. "Once you pull out your appliances, you'll find a lot of places that you need to clean."
If you'd prefer to prevent spillage rather than clean it, you may want to invest in a stove gap cover.
12. Oven
After you tackle the outside of your stove, it's time to clean the inside of the oven. You can try this chemical-free cleaning method to get your oven to look brand-new.
Read more: Your Oven's Bottom Drawer Has a Secret Purpose -- Here's What It Actually Does
Plan to clean your oven about four times a year.
Jevtic/Getty Images
13. Walls
You don't have to clean your walls every day, but they're not immune to getting dirty, especially the ones in your kitchen and bathroom, and for me, the one behind my dog's food and water bowls. You can start by dusting your walls, then using a Magic Eraser on them to get any marks, scuffs or splatters off.
14. Behind the refrigerator
This area can be easily forgotten about, because most people don't routinely pull out their refrigerator. But when you do, you're almost certain to find dust and build up. You can clean the floor underneath your fridge and the wall behind it, then focus on the back of the fridge itself. First, unplug the fridge, then use a microfiber cloth or vacuum to dust the coils.
Dust and hair can even find its way to the back of your fridge.15. Houseplants
It may seem odd at first, but yes, you should be cleaning your houseplants, too -- even fake ones. The leaves on houseplants can collect a lot of dust. You can use a microfiber cloth or a duster to keep them dust-free.
Plants with large leaves are especially likely to get dust buildup.
Polina Sergeyeva/iStock/Getty Images
Expert advice: Create a routine that works for you
While it may seem overwhelming to keep every part of your home clean and free from dust, grease and buildup, don't overwork yourself.
"Work out your own routine and do a little each time," Olive said. "Don't try to tackle everything at once."

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Medscape

36 minutes ago

• Medscape

Fast Five Quiz: Drowning

Drowning is a significant cause of mortality. In the United States, it is the leading cause of death among children aged 1-4 years. Even when not fatal, drowning can result in permanent and severe disability due to prolonged hypoxia. Globally, drowning deaths decreased by 38% between 2000 and 2024. However, in the United States, the drowning mortality rate increased from 2019 to 2022. On average, 11 drowning deaths per day occur in the United States. Do you know the latest facts surrounding drowning? Check your knowledge with this brief quiz. There are major racial/ethnic disparities in drowning deaths and swimming ability in the United States. Although Alaska Native/non-Hispanic American Indian peoples and Black people have the highest drowning rates, the lowest rate of swimming lessons is among Hispanic adults, at only 28.1%. Comparatively, 36.9% of Black adults and 51.8% of White adults have taken swimming lessons. The overall rate of swimming lessons among all US adults is 45.3%. Learn more about drowning epidemiology. A global review on drowning prevention among children and young people found several effective strategies. In addition to placing barriers around bodies of water, the review also found wearing personal flotation devices and removing or covering water hazards to be effective in drowning prevention. Use of solar pool covers was deemed a harmful strategy because unsupervised children have become trapped under these covers and drowned. There have also been cases of drowning deaths among infants placed in baby bath seats in bathtubs. Community-based water safety awareness campaigns were rated as "promising" in the review. Although several campaigns have resulted in increased rates of personal flotation device ownership, the results vary according to the nature of the campaign and its audience. Some campaigns were noted to lack a statistically significant positive impact. Learn more about patient education on drowning. A retrospective cohort study of 406 pediatric drowning patients found that the absence of prehospital cardiac arrest, along with transfer to a high-volume hospital and indoor drowning location, were factors significantly associated with a good clinical outcome. In the study, only one patient died among the 218 patients without prehospital cardiac arrest. However, only five patients had good outcomes among the 188 patients with prehospital cardiac arrest. Patient sex, age, and prehospital time since drowning event were not significantly associated with clinical outcome. Learn more about drowning prognosis. According to American Heart Association/American Academy of Pediatrics guidelines, in-water rescue breathing should be provided to drowning victims by trained rescuers if safe. Guidelines from the Wilderness Medical Society concur. It is not necessary to wait until the patient is on dry land or in a vessel before commencing rescue breathing. Resuscitation of drowning patients should not focus on chest compressions alone. Ventilation and airway management are crucial because cardiac arrest often follows severe hypoxemia in drowning cases. Although it is prudent for water recreation areas to provide automatic external defibrillators, most drowning victims who enter cardiac arrest do not present with defibrillation-responsive rhythms. The Heimlich maneuver is not recommended in drowning because efforts to expel water from the lungs delays resuscitation and might increase the risk for vomiting and aspiration. Learn more about prehospital care in drowning. The Wilderness Medical Society does not recommend empirical antibiotics in the initial management of drowning patients. Although pneumonia might result from aspirated water, the causative microorganisms are often atypical and unresponsive to empirical antibiotic therapies. Additionally, inflammatory pneumonitis resulting from water aspiration and the stress of the drowning event may be mistaken for symptoms of infectious pneumonia. Ideally, before antibiotic administration, pneumonia should be confirmed by urinary antigen testing, sputum cultures, and/or blood cultures. Learn more about the disposition of drowning victims.

Yahoo

36 minutes ago

• Yahoo

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free – – Data presented at ADA simultaneously published in the New England Journal of Medicine – – Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET – BOSTON, June 20, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, "Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy," from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. "These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year." "It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events," said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. "As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future." About Type 1 DiabetesT1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About ZimislecelZimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Investor Event and Webcast Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website. View source version on Contacts Vertex Pharmaceuticals IncorporatedInvestors: InvestorInfo@ Media: mediainfo@ orInternational: +44 20 3204 5275

CBS News

37 minutes ago

• CBS News

Pennsylvania family who stayed at Ronald McDonald house shares their continued message of hope

Bucks County family who stayed at the Ronald McDonald house shares their continued message of hope Bucks County family who stayed at the Ronald McDonald house shares their continued message of hope Bucks County family who stayed at the Ronald McDonald house shares their continued message of hope "Sarah's Painting" was created in a hospital bed by a 9-year-old going through chemotherapy. Michael Pulaski said his daughter, Sarah, loved to paint. "Which was kind of news to us, and she was actually pretty good!" Michael Pulaski said with a chuckle and smile. "It meant something to her, so it meant something to us." Now this picture is taking on a bigger meaning. "Sarah's Painting" CBS News Philadelphia. "It's been, for years, my method of communicating with the world," Sarah's brother, Ryan Pulaski, said. The 22-year-old college student is in the process of making an album. His first single was released Friday, on what would be Sarah's 25th birthday. "In Sarah's Painting, I see visions of life it should be," he sings in the song called "Sarah's Painting." It's inspired by the colorful brush strokes frozen in time. "I feel exceptionally called to create art, and it is only because I had, I have this wonderful sister who was an artist herself, that I was able to find my own voice," Ryan Pulaski said. Pulaski family. In 2010, CBS News Philadelphia caught Sarah's infectious smile on camera while walking the halls of the Children's Hospital of Philadelphia. She talked with us about a Ronald McDonald house family room for the telethon. "When we first met you, it was actually a stressful but promising time, because Sarah was in her first portions of treatment, and she was doing well," Michael Pulaski said. The pre-teen from Richboro went into remission, but later relapsed. At 11 years old, she died after a brave, long battle with leukemia. "This is my absolute favorite picture of the two of them together," Michael Pulaski said, pointing at a photo of Ryan and Sarah. Pulaski family. It's an unbreakable sibling bond — shining through photos, "Sarah's Painting," and now Ryan's song. "She'd probably tell me, I still can't sing," Ryan Pulaski said with a laugh. He continued, "But I think she would love it and be supportive all the same." As for the sibling's dad, "There aren't words, and I'm just proud." The Pulaski family said this story — it's one full of hope, to show others, a picture is worth a thousand words, a thousand memories and a love that lasts a thousand lifetimes. "I think if my 22-year-old son, who's had a probably a more difficult journey than I have, can find hope and joy, then I think the rest of us can too," Michael Pulaski said.